aim
evalu
frequenc
mycoplasma
pneumonia
nasopharyng
specimen
children
respiratori
tract
infect
rti
detail
clinic
characterist
manag
studi
design
retrospect
cohort
studi
children
rti
nucleic
acid
amplif
test
nasopharyng
specimen
analys
clinic
data
extract
electron
health
record
pneumoniaeposit
case
store
sampl
case
random
select
match
control
retest
use
pneumoniaespecif
nucleic
acid
amplif
test
result
children
posit
pneumonia
median
age
iqr
pneumonia
organ
identifi
case
macrolid
treatment
prescrib
prescript
empir
target
differ
regard
patient
age
oxygen
requir
durat
hospitalis
preval
pneumonia
nasopharyng
specimen
children
rti
low
detect
pneumonia
influenc
antibiot
prescript
benefit
earli
empir
versu
target
treatment
remain
unclear
mycoplasma
pneumonia
respiratori
tract
infect
rti
common
particularli
children
young
adult
year
age
pneumonia
caus
upper
lower
rti
shown
common
bacteri
pathogen
communityacquir
pneumonia
togeth
streptococcu
pneumonia
pneumoniaeassoci
rti
often
mild
selflimit
natur
sever
cours
diseas
common
past
detect
pathogenspecif
igm
igg
antibodi
serum
standard
diagnost
test
pneumonia
rti
howev
elev
pneumoniaespecif
serum
antibodi
shown
persist
sever
month
infect
also
common
asymptomat
children
thu
limit
use
detect
acut
infect
molecular
method
diagnosi
pneumonia
therefor
emerg
use
clinic
practic
howev
relationship
detect
pneumonia
nucleic
acid
amplif
test
nasopharyng
specimen
diseas
question
light
evid
also
commonli
abbrevi
cap
communityacquir
pneumonia
cxr
chest
xray
pneumonia
mycoplasma
pneumonia
pcr
polymeras
chain
reaction
rsv
respiratori
syncyti
viru
rti
respiratori
tract
infect
swiss
studi
investig
preval
pneumonia
children
respiratori
tract
infect
rti
children
rti
pneumonia
detect
nucleic
acid
amplif
test
major
organ
detect
suggest
causal
relationship
detect
pneumonia
result
prescript
macrolid
antibiot
major
case
empir
versu
delay
macrolid
treatment
result
improv
shortterm
outcom
detect
among
asymptomat
children
aim
studi
investig
frequenc
pneumonia
routin
nasopharyng
specimen
children
rti
detail
clinic
characterist
manag
pneumoniaeposit
patient
elig
inclus
children
acut
rti
undergo
routin
multiplex
nucleic
acid
amplif
test
nasopharyng
specimen
present
emerg
depart
univers
basel
children
hospit
basel
switzerland
june
decemb
identifi
use
laboratori
record
divis
infect
diagnost
depart
biomedicin
hau
petersplatz
univers
basel
inclus
exclus
criteria
electron
health
record
use
extract
follow
data
age
present
gender
date
present
admiss
statu
clinic
examin
find
result
multiplex
nucleic
acid
amplif
test
nasopharyng
specimen
laboratori
inflammatori
marker
result
chest
radiographi
report
senior
radiologist
oxygen
requir
antibiot
treatment
durat
admiss
data
patient
without
complet
inform
electron
health
record
includ
analysi
specifi
applic
studi
approv
ethic
committe
univers
basel
eknz
nasopharyng
specimen
routin
taken
experienc
clinic
staff
analys
use
commerci
avail
multiplex
nucleic
acid
amplif
test
pathofind
maastricht
netherland
statist
analysi
numer
data
perform
use
mannwhitney
utest
kruskalw
test
categor
data
pearson
chisquar
test
use
pvalu
consid
statist
signific
studi
period
nasopharyng
specimen
obtain
children
median
age
year
acut
rti
undergo
routin
multiplex
nucleic
acid
amplif
test
nasopharyng
specimen
ci
posit
pneumonia
median
age
iqr
year
annual
proport
pneumoniaeposit
sampl
rang
figur
show
agestratifi
number
proport
pneumoniaeposit
versu
neg
case
studi
period
reanalysi
nasopharyng
specimen
match
control
identifi
complet
medic
record
includ
variabl
interest
avail
pneumoniaeposit
case
control
frequent
discharg
diagnos
pneumoniaeposit
case
pneumonia
bronchitisbronchiol
upper
rti
control
discharg
diagnos
divers
upper
rti
pneumonia
bronchitisbronchiol
frequent
record
baselin
characterist
includ
clinic
characterist
group
summaris
tabl
case
pneumonia
organ
detect
nasopharyng
specimen
concomit
organ
identifi
two
one
three
organ
detect
pneumoniaeneg
patient
one
organ
detect
rhinovirusenteroviru
frequent
organ
two
organ
detect
store
nasopharyng
specimen
sampl
pneumoniaeposit
case
pneumoniaeneg
case
avail
retest
use
pneumoniaespecif
nucleic
acid
amplif
test
sampl
suffici
rna
dna
confirm
posit
none
initi
pneumoniaeneg
test
posit
tabl
therefor
pneumoniaespecif
nucleic
acid
amplif
test
store
sampl
show
sensit
specif
antibiot
treatment
case
control
total
case
treat
macrolid
clarithromycin
tabl
case
receiv
macrolid
also
prescrib
concomit
treatment
betalactam
antibiot
case
macrolid
treatment
initi
present
hospit
start
empir
present
target
initi
result
pneumonia
detect
becom
avail
children
receiv
empir
compar
target
macrolid
treatment
statist
differ
age
p
oxygen
requir
p
durat
hospitalis
p
thirteen
case
receiv
antibiot
treatment
case
clinic
improv
discharg
hospit
prior
result
avail
document
reason
withhold
macrolid
treatment
unknown
control
treat
macrolid
tabl
receiv
macrolid
combin
treatment
betalactam
antibiot
addit
control
receiv
betalactam
antibiot
chest
xray
cxr
perform
case
classifi
pneumoniainfiltr
bronchitisbronchi
wall
thicken
normal
one
report
miss
children
neg
pneumonia
detect
cxr
perform
classifi
pneumoniainfiltr
bronchitisbronchi
wall
thicken
normal
one
effus
cxr
commonli
perform
case
compar
control
p
commonli
abnorm
case
p
investig
preval
pneumonia
nasopharyng
specimen
children
rti
sampl
posit
pneumonia
line
find
two
previou
studi
englandwal
germani
pneumonia
detect
pcr
patient
rti
studi
perform
occurr
recent
pneumonia
epidem
europ
recent
studi
describ
much
higher
rate
pneumonia
detect
children
rti
exampl
studi
netherland
includ
children
age
month
year
juli
novemb
show
children
rti
mean
age
year
asymptomat
children
mean
age
year
posit
pneumonia
pcr
importantli
preval
pneumonia
children
rti
lower
year
compar
respect
suggest
consider
yeartoyear
variat
like
influenc
presenc
local
nation
pneumonia
epidem
lower
preval
pneumonia
studi
might
explain
absenc
pneumonia
epidem
region
divers
region
preval
pneumonia
seem
possibl
european
region
countri
time
interv
also
report
increas
pneumonia
preval
unfortun
switzerland
nation
surveil
pneumoniaerel
rti
remain
therefor
difficult
confer
data
whole
countri
younger
age
shown
sever
studi
associ
lower
detect
rate
pneumonia
dutch
studi
mention
preval
pneumonia
nasopharyng
specimen
children
five
year
age
compar
older
children
studi
itali
includ
children
admit
hospit
rti
mean
age
year
show
pneumonia
preval
similarli
studi
chile
includ
children
communityacquir
pneumonia
mean
age
year
posit
pneumonia
pcr
recent
studi
unit
state
show
pneumonia
preval
children
five
year
age
communityacquir
pneumonia
compar
children
age
five
nine
year
year
respect
studi
median
age
children
includ
year
therefor
lower
previou
publish
studi
like
contribut
low
preval
pneumonia
set
younger
age
associ
lower
pneumonia
detect
rate
use
macrolid
prior
test
might
also
influenc
result
effect
antibiot
treatment
may
shorten
period
pneumonia
dna
persist
studi
neg
control
alreadi
treat
macrolid
nasopharyng
specimen
obtain
howev
known
long
dna
might
persist
children
effect
treatment
also
imposs
reconstruct
durat
antimicrobi
treatment
children
receiv
prior
test
use
macrolid
might
influenc
asymptomat
carriag
rate
high
report
expect
higher
pneumonia
rate
studi
includ
case
like
caus
rti
influenza
rsv
howev
proport
pathogen
identifi
low
group
pneumoniaeposit
children
strongli
suggest
detect
pneumonia
nasopharyng
specimen
singl
organ
increas
likelihood
causal
rti
notion
support
anoth
studi
report
symptomat
children
pneumonia
detect
pathogen
identifi
nasopharyng
specimen
limit
data
compar
sensit
upper
versu
lower
respiratori
tract
sampl
pneumonia
howev
avail
evid
indic
case
specimen
posit
thu
detect
pneumonia
nasopharyng
specimen
symptomat
child
lower
rti
strongli
implic
pathogen
caus
pneumonia
interpret
also
line
evid
show
narrow
microbiota
present
nasopharyng
specimen
children
rti
cxr
frequent
perform
abnorm
group
children
pneumonia
detect
nasopharyng
specimen
compar
neg
result
suggest
associ
pneumonia
posit
result
detect
pneumonia
led
chang
empir
antibiot
treatment
almost
half
case
present
studi
howev
data
efficaci
macrolid
treatment
controversi
two
recent
systemat
review
conclud
insuffici
evid
draw
conclus
efficaci
macrolid
treatment
pneumonia
lower
rti
children
despit
fact
consider
evid
antiinflammatori
properti
agent
interestingli
studi
shortterm
treatment
benefit
reduc
oxygen
requir
shorter
hospit
stay
found
compar
patient
empir
administr
macrolid
prescript
hour
later
pneumonia
infect
confirm
nucleic
acid
amplif
test
consist
anoth
recent
publish
studi
fail
show
signific
differ
durat
admiss
children
pneumoniaeposit
communityacquir
pneumonia
treat
macrolid
compar
treatment
one
potenti
limit
studi
emerg
depart
multiplex
nucleic
acid
amplif
test
np
standard
diagnost
tool
children
requir
admiss
may
lead
bia
test
children
clinic
sever
rti
present
therebi
render
find
applic
children
mild
rti
limit
potenti
lower
sensit
multiplex
pcr
assay
howev
retest
store
sampl
independ
pneumoniaespecif
nucleic
acid
amplif
test
suggest
lower
sensit
line
recent
result
howev
sensit
may
also
influenc
storag
exclud
current
studi
set
studi
done
limit
region
time
frame
may
limit
generalis
studi
result
result
comparison
result
group
neg
pneumonia
test
requir
cautiou
interpret
repres
small
potenti
nonrepres
group
pneumoniaeneg
patient
multiplex
nucleic
acid
amplif
test
sensit
screen
tool
detect
pneumonia
influenc
antibiot
prescript
empir
treatment
result
shorter
admiss
durat
view
uncertainti
efficaci
antibiot
treatment
increas
antibiot
resist
worldwid
signific
pneumonia
detect
children
rti
need
investig
jab
declar
husband
employ
novarti
author
noth
declar
studi
receiv
extern
fund
